Skip to main content
Smart Investors Daily
NR

NASDAQ · NRIX

Nurix Therapeutics, Inc.

Healthcare · Biotechnology

$13.60

Down-$0.50 (-3.55%)

Updated Nov 20, 2026, 2:38 AM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.47B
P/E ratio
-6.56
Dividend yield
0.00%
52-week range
$12.43 – $28.23
Volume
2.26M
Avg. volume
1.68M

Price performance · NRIX

NRIX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

NRIX closed at $13.60 after 21 trading sessions, down 46.69% for the selected period.

Last close
$13.60
Period change
-46.69%
Period low
$13.60
Period high
$27.26
Daily close
View OHLC price history
NRIX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$14.21$14.39$13.545$13.602.26M
Nov 18, 2026$14.18$14.44$13.65$14.102.79M
Nov 17, 2026$14.80$14.87$14.11$14.242.23M
Nov 16, 2026$15.34$15.68$14.68$14.732.16M
Nov 13, 2026$15.50$15.76$15.19$15.481.39M
Nov 12, 2026$16.39$16.55$15.545$15.601.34M
Nov 11, 2026$16.00$16.70$15.915$16.332.98M
Nov 10, 2026$16.00$16.76$15.75$15.883.05M
Nov 9, 2026$15.32$16.63$15.265$16.147.6M
Nov 6, 2026$15.10$15.52$14.791$15.302.98M
Nov 5, 2026$16.01$16.5939$14.80$14.847.09M
Nov 4, 2026$17.16$17.28$14.78$15.9519.56M
Nov 3, 2026$25.72$26.55$25.6325$25.824.39M
Nov 2, 2026$26.75$26.9569$25.532$25.702.35M
Oct 30, 2026$26.90$26.915$25.97$26.802.31M
Oct 29, 2026$27.46$27.99$26.685$27.122.38M
Oct 28, 2026$26.26$27.28$25.45$27.261.96M
Oct 27, 2026$25.52$27.05$25.13$26.702.56M
Oct 26, 2026$25.35$25.82$25.03$25.552.34M
Oct 23, 2026$25.22$25.49$24.775$25.341.91M
Oct 22, 2026$25.86$26.225$25.1801$25.511.93M

Latest NRIX news

The latest Smart Investors Daily articles mentioning NRIX.

NRIX research

Overview

Company profile and research snapshot.

Company profile

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$27.78
Implied upside
—
Analysts
—
NRIX recent ratings
DateFirmRatingTarget
Nov 4, 2026Wells FargoEqual-Weight—
Oct 16, 2026HC Wainwright & Co.Buy—
Oct 13, 2026Truist SecuritiesBuy—
Oct 13, 2026RBC CapitalOutperform—
Oct 13, 2026OppenheimerOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 11, 2026

Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer

Physician-scientist and oncology leader brings more than two decades of experience in academic medicine, global clinical development and regulatory submissions Nurix Therapeutics Chief Medical Officer Arati V. Rao, M.D., Nurix Therapeutics Chief Medical Officer BRISBANE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines,

Yahoo · Nov 10, 2026

Nurix Therapeutics to Participate in Upcoming Investor Conferences

BRISBANE, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Company management will participate in fireside chats at the following investor conferences: UBS Global Biopharma ConferenceTuesday, November 17, 2026, at 2:40 p.m. GMTJefferies Global Healthcare ConferenceWednesday, November 18, 2026, at 1

Yahoo · Nov 7, 2026

Is Early B Cell Cancer Data Altering The Investment Case For Nurix Therapeutics (NRIX)?

Nurix Therapeutics reported that Sanofi terminated the Phase 1 trial and broader SAR448272 STAT6 degrader program, while Nurix remains eligible for milestones and royalties from other partnered assets. Separately, Nurix highlighted new Phase 1a/1b data for bexobrutideg in relapsed or refractory CLL/SLL showing high response rates and continued favorable tolerability. The loss of one STAT6 program reduces potential collaboration inflows. However, fresh bexobrutideg data supports Nurix...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.